JP6276258B2 - ＯｓｐＡの変異型断片、並びにそれに関する方法および使用 - Google Patents

ＯｓｐＡの変異型断片、並びにそれに関する方法および使用 Download PDF

Info

Publication number
JP6276258B2
JP6276258B2 JP2015519248A JP2015519248A JP6276258B2 JP 6276258 B2 JP6276258 B2 JP 6276258B2 JP 2015519248 A JP2015519248 A JP 2015519248A JP 2015519248 A JP2015519248 A JP 2015519248A JP 6276258 B2 JP6276258 B2 JP 6276258B2
Authority
JP
Japan
Prior art keywords
ospa
disulfide bond
seq
bond type
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015519248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522270A (ja
JP2015522270A5 (enExample
Inventor
ペール コムステット
ペール コムステット
ウルバン ランドベルク
ウルバン ランドベルク
アンドレアス マインケ
アンドレアス マインケ
マルクス ハンナー
マルクス ハンナー
ウォルフガング シューラ—
ウォルフガング シューラ―
ベンジャミン ワイゼル
ベンジャミン ワイゼル
クリストフ ライニッシュ
クリストフ ライニッシュ
ブリジット グローマン
ブリジット グローマン
ロバート シュレグル
ロバート シュレグル
Original Assignee
バルネバ オーストリア ゲーエムベーハ—
バルネバ オーストリア ゲーエムベーハ―
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バルネバ オーストリア ゲーエムベーハ—, バルネバ オーストリア ゲーエムベーハ― filed Critical バルネバ オーストリア ゲーエムベーハ—
Publication of JP2015522270A publication Critical patent/JP2015522270A/ja
Publication of JP2015522270A5 publication Critical patent/JP2015522270A5/ja
Application granted granted Critical
Publication of JP6276258B2 publication Critical patent/JP6276258B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015519248A 2012-07-06 2013-07-08 ＯｓｐＡの変異型断片、並びにそれに関する方法および使用 Active JP6276258B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US61/668,627 2012-07-06
US13/802,991 2013-03-14
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (3)

Publication Number Publication Date
JP2015522270A JP2015522270A (ja) 2015-08-06
JP2015522270A5 JP2015522270A5 (enExample) 2015-09-17
JP6276258B2 true JP6276258B2 (ja) 2018-02-07

Family

ID=49878705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519248A Active JP6276258B2 (ja) 2012-07-06 2013-07-08 ＯｓｐＡの変異型断片、並びにそれに関する方法および使用

Country Status (24)

Country Link
US (9) US8986704B2 (enExample)
EP (3) EP2869839B1 (enExample)
JP (1) JP6276258B2 (enExample)
KR (2) KR102190981B1 (enExample)
CN (2) CN104487084B (enExample)
AU (2) AU2013285364B2 (enExample)
CA (1) CA2876541C (enExample)
CY (1) CY1120772T1 (enExample)
DK (1) DK2869839T3 (enExample)
EA (2) EA201991059A1 (enExample)
ES (2) ES2688883T3 (enExample)
HR (1) HRP20181689T1 (enExample)
HU (1) HUE041286T2 (enExample)
LT (1) LT2869839T (enExample)
MX (2) MX364623B (enExample)
NZ (2) NZ733026A (enExample)
PL (1) PL2869839T3 (enExample)
PT (1) PT2869839T (enExample)
RS (1) RS57847B1 (enExample)
SI (1) SI2869839T1 (enExample)
SM (1) SMT201800557T1 (enExample)
TR (1) TR201815419T4 (enExample)
WO (1) WO2014006226A1 (enExample)
ZA (1) ZA201409222B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170016988A (ko) * 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HRP20191086T1 (hr) * 2014-01-09 2019-11-01 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
EP3393481A1 (en) * 2015-12-23 2018-10-31 Novartis Ag Oil-in-water emulsions including retinoic acid
WO2017139715A1 (en) * 2016-02-11 2017-08-17 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) * 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8420352B2 (en) 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
KR20180082633A (ko) 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
DK3785730T3 (da) 2011-12-06 2024-05-06 Valneva Austria Gmbh Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
EP2788200B1 (en) 2011-12-06 2018-07-04 Mubea Carbo Tech GmbH Wheel made out of fiber reinforced material and procedure to make an according wheel
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HRP20191086T1 (hr) 2014-01-09 2019-11-01 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP3387006A4 (en) 2015-12-10 2019-05-08 National Research Council of Canada LIPIDATED STREPTOCOCCUS PNEUMONIAE
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
US10787501B1 (en) 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170016988A (ko) * 2014-06-27 2017-02-14 우베 고산 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염

Also Published As

Publication number Publication date
US9926343B2 (en) 2018-03-27
CN107602676B (zh) 2021-06-04
HK1209370A1 (en) 2016-04-01
EA201991059A1 (ru) 2020-01-31
EP3360568A1 (en) 2018-08-15
CY1120772T1 (el) 2019-12-11
US20170107263A1 (en) 2017-04-20
HK1257893A1 (en) 2019-11-01
EP3689372A1 (en) 2020-08-05
US11466058B2 (en) 2022-10-11
US20220185851A1 (en) 2022-06-16
KR102393038B1 (ko) 2022-04-29
US20140010835A1 (en) 2014-01-09
AU2013285364A1 (en) 2015-01-29
DK2869839T3 (en) 2018-10-15
EA033007B1 (ru) 2019-08-30
CN104487084B (zh) 2017-09-22
HRP20181689T1 (hr) 2018-12-28
US12195501B2 (en) 2025-01-14
EA201590162A1 (ru) 2015-06-30
MX391136B (es) 2025-03-21
PL2869839T3 (pl) 2018-12-31
AU2017218974C1 (en) 2020-02-20
US20170101446A1 (en) 2017-04-13
US8986704B2 (en) 2015-03-24
SMT201800557T1 (it) 2018-11-09
ES2688883T3 (es) 2018-11-07
AU2017218974A1 (en) 2017-09-07
CA2876541A1 (en) 2014-01-09
CN104487084A (zh) 2015-04-01
HK1207982A1 (en) 2016-02-19
JP2015522270A (ja) 2015-08-06
US20150250865A1 (en) 2015-09-10
SI2869839T1 (sl) 2018-11-30
CA2876541C (en) 2022-03-01
TR201815419T4 (tr) 2018-11-21
KR20200141096A (ko) 2020-12-17
US20150232517A1 (en) 2015-08-20
EP2869839A1 (en) 2015-05-13
RS57847B1 (sr) 2018-12-31
EP3360568B1 (en) 2020-03-04
ZA201409222B (en) 2016-08-31
US20230295245A1 (en) 2023-09-21
EP2869839B1 (en) 2018-09-05
KR20150036191A (ko) 2015-04-07
AU2017218974B2 (en) 2019-05-30
HK1248244A1 (zh) 2018-10-12
US10544194B2 (en) 2020-01-28
AU2013285364B2 (en) 2017-06-15
MX2015000013A (es) 2015-06-04
US20200239525A1 (en) 2020-07-30
US11208439B2 (en) 2021-12-28
ES2800873T3 (es) 2021-01-04
PT2869839T (pt) 2018-11-12
KR102190981B1 (ko) 2020-12-15
MX364623B (es) 2019-05-03
CN107602676A (zh) 2018-01-19
NZ703597A (en) 2017-06-30
US20180327460A1 (en) 2018-11-15
NZ733026A (en) 2019-09-27
HUE041286T2 (hu) 2019-05-28
WO2014006226A1 (en) 2014-01-09
LT2869839T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
US20230295245A1 (en) Mutant fragments of ospa and methods and uses relating thereto
HK40035688A (en) Mutant fragments of ospa and methods and uses relating thereto
HK1257893B (en) Mutant fragments of ospa and methods and uses relating thereto
HK1207982B (en) Mutant fragments of ospa and methods and uses relating thereto
EA046886B1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
HK1209370B (en) Mutant fragments of ospa and methods and uses relating thereto
HK1248244B (zh) Ospa的突变片段以及其相关方法和用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160413

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180111

R150 Certificate of patent or registration of utility model

Ref document number: 6276258

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250